

# The NEW ENGLAND JOURNAL of MEDICINE

ESTABLISHED IN 1812

APRIL 4, 2013

VOL. 368 NO. 14

## Primary Prevention of Cardiovascular Disease with a Mediterranean Diet

Ramón Estruch, M.D., Ph.D., Emilio Ros, M.D., Ph.D., Jordi Salas-Salvadó, M.D., Ph.D.,  
Maria-Isabel Covas, D.Pharm., Ph.D., Dolores Corella, D.Pharm., Ph.D., Fernando Arós, M.D., Ph.D.,  
Enrique Gómez-Gracia, M.D., Ph.D., Valentina Ruiz-Gutiérrez, Ph.D., Miquel Fiol, M.D., Ph.D.,  
José Lapetra, M.D., Ph.D., Rosa Maria Lamuela-Raventos, D.Pharm., Ph.D., Lluís Serra-Majem, M.D., Ph.D.,  
Xavier Pintó, M.D., Ph.D., Josep Basora, M.D., Ph.D., Miguel Angel Muñoz, M.D., Ph.D., José V. Sorlí, M.D., Ph.D.,  
José Alfredo Martínez, D.Pharm, M.D., Ph.D., and Miguel Angel Martínez-González, M.D., Ph.D.,  
for the PREDIMED Study Investigators\*

### ABSTRACT

#### BACKGROUND

Observational cohort studies and a secondary prevention trial have shown an inverse association between adherence to the Mediterranean diet and cardiovascular risk. We conducted a randomized trial of this diet pattern for the primary prevention of cardiovascular events.

#### METHODS

In a multicenter trial in Spain, we randomly assigned participants who were at high cardiovascular risk, but with no cardiovascular disease at enrollment, to one of three diets: a Mediterranean diet supplemented with extra-virgin olive oil, a Mediterranean diet supplemented with mixed nuts, or a control diet (advice to reduce dietary fat). Participants received quarterly individual and group educational sessions and, depending on group assignment, free provision of extra-virgin olive oil, mixed nuts, or small nonfood gifts. The primary end point was the rate of major cardiovascular events (myocardial infarction, stroke, or death from cardiovascular causes). On the basis of the results of an interim analysis, the trial was stopped after a median follow-up of 4.8 years.

#### RESULTS

A total of 7447 persons were enrolled (age range, 55 to 80 years); 57% were women. The two Mediterranean-diet groups had good adherence to the intervention, according to self-reported intake and biomarker analyses. A primary end-point event occurred in 288 participants. The multivariable-adjusted hazard ratios were 0.70 (95% confidence interval [CI], 0.54 to 0.92) and 0.72 (95% CI, 0.54 to 0.96) for the group assigned to a Mediterranean diet with extra-virgin olive oil (96 events) and the group assigned to a Mediterranean diet with nuts (83 events), respectively, versus the control group (109 events). No diet-related adverse effects were reported.

#### CONCLUSIONS

Among persons at high cardiovascular risk, a Mediterranean diet supplemented with extra-virgin olive oil or nuts reduced the incidence of major cardiovascular events. (Funded by the Spanish government's Instituto de Salud Carlos III and others; Controlled-Trials.com number, ISRCTN35739639.)

The authors' affiliations are listed in the Appendix. Address reprint requests to Dr. Estruch at the Department of Internal Medicine, Hospital Clinic, Villarroel 170, 08036 Barcelona, Spain, or at [restruch@clinic.ub.es](mailto:restruch@clinic.ub.es), or to Dr. Martínez-González at the Department of Preventive Medicine and Public Health, Facultad de Medicina—Clínica Universidad de Navarra, Irunlarrea 1, 31008 Pamplona, Spain, or at [mamartinez@unav.es](mailto:mamartinez@unav.es).

\*The PREDIMED (Prevención con Dieta Mediterránea) study investigators are listed in the Supplementary Appendix, available at [NEJM.org](http://NEJM.org).

Drs. Estruch and Martínez-González contributed equally to this article.

This article was published on February 25, 2013, at [NEJM.org](http://NEJM.org).

*N Engl J Med* 2013;368:1279-90.

DOI: 10.1056/NEJMoa1200303

Copyright © 2013 Massachusetts Medical Society.

**T**HE TRADITIONAL MEDITERRANEAN DIET is characterized by a high intake of olive oil, fruit, nuts, vegetables, and cereals; a moderate intake of fish and poultry; a low intake of dairy products, red meat, processed meats, and sweets; and wine in moderation, consumed with meals.<sup>1</sup> In observational cohort studies<sup>2,3</sup> and a secondary prevention trial (the Lyon Diet Heart Study),<sup>4</sup> increasing adherence to the Mediterranean diet has been consistently beneficial with respect to cardiovascular risk.<sup>2-4</sup> A systematic review ranked the Mediterranean diet as the most likely dietary model to provide protection against coronary heart disease.<sup>5</sup> Small clinical trials have uncovered plausible biologic mechanisms to explain the salutary effects of this food pattern.<sup>6-9</sup> We designed a randomized trial to test the efficacy of two Mediterranean diets (one supplemented with extra-virgin olive oil and another with nuts), as compared with a control diet (advice on a low-fat diet), on primary cardiovascular prevention.

## METHODS

### STUDY DESIGN

The PREDIMED trial (Prevención con Dieta Mediterránea) was a parallel-group, multicenter, randomized trial. Details of the trial design are provided elsewhere.<sup>10-12</sup> The trial was designed and conducted by the authors, and the protocol was approved by the institutional review boards at all study locations. The authors vouch for the accuracy and completeness of the data and all analyses and for the fidelity of this report to the protocol, which is available with the full text of this article at NEJM.org.

Supplemental foods were donated, including extra-virgin olive oil (by Hojiblanca and Patrimonio Comunal Olivarero, both in Spain), walnuts (by the California Walnut Commission), almonds (by Borges, in Spain), and hazelnuts (by La Morella Nuts, in Spain). None of the sponsors had any role in the trial design, data analysis, or reporting of the results.

### PARTICIPANT SELECTION AND RANDOMIZATION

Eligible participants were men (55 to 80 years of age) and women (60 to 80 years of age) with no cardiovascular disease at enrollment, who had either type 2 diabetes mellitus or at least three of the following major risk factors: smoking, hypertension, elevated low-density lipoprotein

cholesterol levels, low high-density lipoprotein cholesterol levels, overweight or obesity, or a family history of premature coronary heart disease. Detailed enrollment criteria are provided in the Supplementary Appendix, available at NEJM.org. All participants provided written informed consent.

Beginning on October 1, 2003, participants were randomly assigned, in a 1:1:1 ratio, to one of three dietary intervention groups: a Mediterranean diet supplemented with extra-virgin olive oil, a Mediterranean diet supplemented with nuts, or a control diet. Randomization was performed centrally by means of a computer-generated random-number sequence.

### INTERVENTIONS AND MEASUREMENTS

The dietary intervention<sup>8,10-13</sup> is detailed in the Supplementary Appendix. The specific recommended diets are summarized in Table 1. Participants in the two Mediterranean-diet groups received either extra-virgin olive oil (approximately 1 liter per week) or 30 g of mixed nuts per day (15 g of walnuts, 7.5 g of hazelnuts, and 7.5 g of almonds) at no cost, and those in the control group received small nonfood gifts. No total calorie restriction was advised, nor was physical activity promoted.

For participants in the two Mediterranean-diet groups, dietitians ran individual and group dietary-training sessions at the baseline visit and quarterly thereafter. In each session, a 14-item dietary screener was used to assess adherence to the Mediterranean diet<sup>8,14</sup> (Table S1 in the Supplementary Appendix) so that personalized advice could be provided to the study participants in these groups.

Participants in the control group also received dietary training at the baseline visit and completed the 14-item dietary screener used to assess baseline adherence to the Mediterranean diet. Thereafter, during the first 3 years of the trial, they received a leaflet explaining the low-fat diet (Table S2 in the Supplementary Appendix) on a yearly basis. However, the realization that the more infrequent visit schedule and less intense support for the control group might be limitations of the trial prompted us to amend the protocol in October 2006. Thereafter, participants assigned to the control diet received personalized advice and were invited to group sessions with the same frequency and intensity as those in the Mediterranean-diet groups, with

the use of a separate 9-item dietary screener (Table S3 in the Supplementary Appendix).

A general medical questionnaire, a 137-item validated food-frequency questionnaire,<sup>15</sup> and the Minnesota Leisure-Time Physical Activity Questionnaire were administered on a yearly basis.<sup>10</sup> Information from the food-frequency questionnaire was used to calculate intake of energy and nutrients. Weight, height, and waist circumference were directly measured.<sup>16</sup> Biomarkers of compliance, including urinary hydroxytyrosol levels (to confirm compliance in the group receiving extra-virgin olive oil) and plasma alpha-linolenic acid levels (to confirm compliance in the group receiving mixed nuts), were measured in random subsamples of participants at 1, 3, and 5 years (see the Supplementary Appendix).

#### END POINTS

The primary end point was a composite of myocardial infarction, stroke, and death from cardiovascular causes. Secondary end points were stroke, myocardial infarction, death from cardiovascular causes, and death from any cause. We used four sources of information to identify end points: repeated contacts with participants, contacts with family physicians, a yearly review of medical records, and consultation of the National Death Index. All medical records related to end points were examined by the end-point adjudication committee, whose members were unaware of the study-group assignments. Only end points that were confirmed by the adjudication committee and that occurred between October 1, 2003, and December 1, 2010, were included in the analyses. The criteria for adjudicating primary and secondary end points are detailed in the Supplementary Appendix.

#### STATISTICAL ANALYSIS

We initially estimated that a sample of 9000 participants would be required to provide statistical power of 80% to detect a relative risk reduction of 20% in each Mediterranean-diet group versus the control-diet group during a 4-year follow-up period, assuming an event rate of 12% in the control group.<sup>10,17</sup> In April 2008, on the advice of the data and safety monitoring board and on the basis of lower-than-expected rates of end-point events, the sample size was recalculated as 7400 participants, with the assumption of a 6-year follow-up period and underlying event rates of

**Table 1. Summary of Dietary Recommendations to Participants in the Mediterranean-Diet Groups and the Control-Diet Group.**

Food	Goal
<b>Mediterranean diet</b>	
Recommended	
Olive oil*	≥4 tbsp/day
Tree nuts and peanuts†	≥3 servings/wk
Fresh fruits	≥3 servings/day
Vegetables	≥2 servings/day
Fish (especially fatty fish), seafood	≥3 servings/wk
Legumes	≥3 servings/wk
Sofrito‡	≥2 servings/wk
White meat	Instead of red meat
Wine with meals (optionally, only for habitual drinkers)	≥7 glasses/wk
Discouraged	
Soda drinks	<1 drink/day
Commercial bakery goods, sweets, and pastries§	<3 servings/wk
Spread fats	<1 serving/day
Red and processed meats	<1 serving/day
<b>Low-fat diet (control)</b>	
Recommended	
Low-fat dairy products	≥3 servings/day
Bread, potatoes, pasta, rice	≥3 servings/day
Fresh fruits	≥3 servings/day
Vegetables	≥2 servings/wk
Lean fish and seafood	≥3 servings/wk
Discouraged	
Vegetable oils (including olive oil)	≤2 tbsp/day
Commercial bakery goods, sweets, and pastries§	≤1 serving/wk
Nuts and fried snacks	≤1 serving /wk
Red and processed fatty meats	≤1 serving/wk
Visible fat in meats and soups¶	Always remove
Fatty fish, seafood canned in oil	≤1 serving/wk
Spread fats	≤1 serving/wk
Sofrito‡	≤2 servings/wk

\* The amount of olive oil includes oil used for cooking and salads and oil consumed in meals eaten outside the home. In the group assigned to the Mediterranean diet with extra-virgin olive oil, the goal was to consume 50 g (approximately 4 tbsp) or more per day of the polyphenol-rich olive oil supplied, instead of the ordinary refined variety, which is low in polyphenols.

† For participants assigned to the Mediterranean diet with nuts, the recommended consumption was one daily serving (30 g, composed of 15 g of walnuts, 7.5 g of almonds, and 7.5 g of hazelnuts).

‡ Sofrito is a sauce made with tomato and onion, often including garlic and aromatic herbs, and slowly simmered with olive oil.

§ Commercial bakery goods, sweets, and pastries (not homemade) included cakes, cookies, biscuits, and custard.

¶ Participants were advised to remove the visible fat (or the skin) of chicken, duck, pork, lamb, or veal before cooking and the fat of soups, broths, and cooked meat dishes before consumption.

8.8% and 6.6% in the control and intervention groups, respectively. Power curves under several assumptions can be found in Figure S1 in the Supplementary Appendix.

Yearly interim analyses began after a median of 2 years of follow-up. With the use of O'Brien–Fleming stopping boundaries, the P values for stopping the trial at each yearly interim analysis were  $5 \times 10^{-6}$ , 0.001, 0.009, and 0.02 for benefit and  $9 \times 10^{-5}$ , 0.005, 0.02, and 0.05 for adverse effects.<sup>18</sup> The stopping boundary for the benefit of the Mediterranean diets with respect to the primary end point was crossed at the fourth interim evaluation; on July 22, 2011, the data and safety monitoring board recommended stopping the trial on the basis of end points documented through December 1, 2010.

All primary analyses were performed on an intention-to-treat basis by two independent analysts. Time-to-event data were analyzed with the use of Cox models with two dummy variables (one for the Mediterranean diet with extra-virgin olive oil and another for the Mediterranean diet

with nuts) to obtain two hazard ratios for the comparison with the control group. To account for small imbalances in risk factors at baseline among the groups, Cox regression models were used to adjust for sex, age, and baseline risk factors. We tested the proportionality of hazards with the use of time-varying covariates. All analyses were stratified according to center. Prespecified subgroup analyses were conducted according to sex, age, body-mass index (BMI), cardiovascular-risk-factor status, and baseline adherence to the Mediterranean diet. Sensitivity analyses were conducted under several assumptions, including imputation of data for missing values and participants who dropped out (see the Supplementary Appendix).

## RESULTS

### BASELINE CHARACTERISTICS OF THE STUDY

#### PARTICIPANTS

From October 2003 through June 2009, a total of 8713 candidates were screened for eligibility, and

**Table 2. Baseline Characteristics of the Participants According to Study Group.\***

Characteristic	Mediterranean Diet with EVOO (N=2543)	Mediterranean Diet with Nuts (N=2454)	Control Diet (N=2450)
Female sex — no. (%)†	1493 (58.7)	1326 (54.0)	1463 (59.7)
Age — yr†	67.0±6.2	66.7±6.1	67.3±6.3
Race or ethnic group — no. (%)			
White, from Europe	2470 (97.1)	2390 (97.4)	2375 (96.9)
Hispanic, from Central or South America	35 (1.4)	29 (1.2)	38 (1.6)
Other	38 (1.5)	35 (1.4)	37 (1.5)
Smoking status — no. (%)			
Never smoked	1572 (61.8)	1465 (59.7)	1527 (62.3)
Former smoker	618 (24.3)	634 (25.8)	584 (23.8)
Current smoker	353 (13.9)	355 (14.5)	339 (13.8)
Body-mass index†‡			
Mean	29.9±3.7	29.7±3.8	30.2±4.0
<25 — no. (%)	195 (7.7)	204 (8.3)	164 (6.7)
25–30 — no. (%)	1153 (45.3)	1163 (47.4)	1085 (44.3)
>30 — no. (%)	1195 (47.0)	1087 (44.3)	1201 (49.0)
Waist circumference — cm	100±10	100±11	101±11
Waist-to-height ratio†§	0.63±0.06	0.63±0.06	0.63±0.07
Hypertension — no. (%)¶	2088 (82.1)	2024 (82.5)	2050 (83.7)
Type 2 diabetes — no. (%)†	1282 (50.4)	1143 (46.6)	1189 (48.5)
Dyslipidemia — no. (%)**	1821 (71.6)	1799 (73.3)	1763 (72.0)
Family history of premature CHD — no. (%)††	576 (22.7)	532 (21.7)	560 (22.9)

Table 2. (Continued.)

Characteristic	Mediterranean Diet with EVOO (N=2543)	Mediterranean Diet with Nuts (N=2454)	Control Diet (N=2450)
Medication use — no. (%)			
ACE inhibitors	1236 (48.6)	1223 (49.8)	1216 (49.6)
Diuretics†	534 (21.0)	477 (19.4)	562 (22.9)
Other antihypertensive agents	725 (28.5)	710 (28.9)	758 (30.9)
Statins	1039 (40.9)	964 (39.3)	983 (40.1)
Other lipid-lowering agents	121 (4.8)	145 (5.9)	126 (5.1)
Insulin	124 (4.9)	126 (5.1)	134 (5.5)
Oral hypoglycemic agents†	768 (30.2)	680 (27.7)	757 (30.9)
Antiplatelet therapy	475 (18.7)	490 (20.0)	513 (20.9)
Hormone-replacement therapy‡‡	42 (2.8)	35 (2.6)	39 (2.7)
Score for adherence to Med diet§§	8.7±2.0	8.7±2.0	8.4±2.1

- \* Plus-minus values are means ±SD. ACE denotes angiotensin-converting enzyme, and EVOO extra-virgin olive oil.
- † P<0.05 for comparisons between groups.
- ‡ The body-mass index is the weight in kilograms divided by the square of the height in meters.
- § The waist-to-height ratio (an index of central obesity) is the waist circumference divided by height.
- ¶ Hypertension was defined as a systolic blood pressure of 140 mm Hg or higher, a diastolic blood pressure of 90 mm Hg or higher, or the use of antihypertensive therapy.
- || Diabetes was defined as a fasting blood glucose level of 126 mg per deciliter (7.0 mmol per liter) or higher on two occasions, a 2-hour plasma glucose level of 200 mg per deciliter (11 mmol per liter) or higher during a 75-g oral glucose-tolerance test, or the use of antidiabetic medication.
- \*\* Dyslipidemia was defined as a low-density lipoprotein cholesterol level higher than 160 mg per deciliter (4.1 mmol per liter), a high-density lipoprotein cholesterol level of 40 mg per deciliter (1.0 mmol per liter) or lower in men or 50 mg per deciliter (1.3 mmol per liter) or lower in women, or the use of lipid-lowering therapy.
- †† A family history of premature coronary heart disease (CHD) was defined as a diagnosis of the disease in a male first-degree relative younger than 55 years of age or in a female first-degree relative younger than 65 years of age.
- ‡‡ The values for hormone-replacement therapy are for women only.
- §§ The score for adherence to the Mediterranean diet is based on the 14-item dietary screener shown in Table S1 in the Supplementary Appendix (a score of 0 indicates minimum adherence, and a score of 14 indicates maximum adherence).

7447 were randomly assigned to one of the three study groups (Fig. S2 in the Supplementary Appendix). Their baseline characteristics according to study group are shown in Table 2. Drug-treatment regimens were similar for participants in the three groups, and they continued to be balanced during the follow-up period (Table S4 in the Supplementary Appendix).

Participants were followed for a median of 4.8 years (interquartile range, 2.8 to 5.8). After the initial assessment, 209 participants (2.8%) chose not to attend subsequent visits, and their follow-up was based on reviews of medical records. By December 2010, a total of 523 participants (7.0%) had been lost to follow-up for 2 or more years. Dropout rates were higher in the control group (11.3%) than in the Mediterranean-diet groups (4.9%) (Fig. S2 in the Supplementary Appendix). As compared with participants who remained in the trial, those who dropped out

were younger (by 1.4 years), had a higher BMI (the weight in kilograms divided by the square of the height in meters; by 0.4), a higher waist-to-height ratio (by 0.01), and a lower score for adherence to the Mediterranean diet (by 1.0 points on the 14-item dietary screener) (P<0.05 for all comparisons).

#### COMPLIANCE WITH THE DIETARY INTERVENTION

Participants in the three groups reported similar adherence to the Mediterranean diet at baseline (Table 2, and Fig. S3 in the Supplementary Appendix) and similar food and nutrient intakes. During follow-up, scores on the 14-item Mediterranean-diet screener increased for the participants in the two Mediterranean-diet groups (Fig. S3 in the Supplementary Appendix). There were significant differences between these groups and the control group in 12 of the 14 items at 3 years (Table S5 in the Supplementary Appen-

dix). Changes in objective biomarkers also indicated good compliance with the dietary assignments (Fig. S4 and S5 in the Supplementary Appendix).

Participants in the two Mediterranean-diet groups significantly increased weekly servings of fish (by 0.3 servings) and legumes (by 0.4 servings) in comparison with those in the control group (Table S6 in the Supplementary Appendix). In addition, participants assigned to a Mediterranean diet with extra-virgin olive oil and those assigned to a Mediterranean diet with nuts sig-

nificantly increased their consumption of extra-virgin olive oil (to 50 and 32 g per day, respectively) and nuts (to 0.9 and 6 servings per week, respectively). The main nutrient changes in the Mediterranean-diet groups reflected the fat content and composition of the supplemental foods (Tables S7 and S8 in the Supplementary Appendix). No relevant diet-related adverse effects were reported (see the Supplementary Appendix). We did not find any significant difference in changes in physical activity among the three groups.

**Table 3. Outcomes According to Study Group.\***

End Point	Mediterranean Diet with EVOO (N=2543)	Mediterranean Diet with Nuts (N=2454)	Control Diet (N=2450)	P Value†	
				Mediterranean Diet with EVOO vs. Control Diet	Mediterranean Diet with Nuts vs. Control Diet
Person-yr of follow-up	11,852	10,365	9763		
Primary end point‡					
No. of events	96	83	109		
Crude rate/1000 person-yr (95% CI)	8.1 (6.6–9.9)	8.0 (6.4–9.9)	11.2 (9.2–13.5)	0.009	0.02
Secondary end points					
Stroke					
No. of events	49	32	58		
Crude rate/1000 person-yr (95% CI)	4.1 (3.1–5.5)	3.1 (2.1–4.4)	5.9 (4.5–7.7)	0.03	0.003
Myocardial infarction					
No. of events	37	31	38		
Crude rate/1000 person-yr (95% CI)	3.1 (2.2–4.3)	3.0 (2.0–4.2)	3.9 (2.8–5.3)	0.31	0.25
Death from cardiovascular causes					
No. of events	26	31	30		
Crude rate/1000 person-yr (95% CI)	2.2 (1.4–3.2)	3.0 (2.0–4.2)	3.1 (2.1–4.4)	0.15	0.85
Death from any cause					
No. of events	118	116	114		
Crude rate/1000 person-yr (95% CI)	10.0 (8.2–11.9)	11.2 (9.3–13.4)	11.7 (9.6–14.0)	0.11	0.68
Hazard ratio for each Mediterranean diet vs. control (95% CI)					
Primary end point					
Unadjusted	0.70 (0.53–0.91)	0.70 (0.53–0.94)	1.00 (ref)	0.009	0.02
Multivariable-adjusted 1§	0.69 (0.53–0.91)	0.72 (0.54–0.97)	1.00 (ref)	0.008	0.03
Multivariable-adjusted 2¶	0.70 (0.54–0.92)	0.72 (0.54–0.96)	1.00 (ref)	0.01	0.03
Secondary end points					
Stroke	0.67 (0.46–0.98)	0.54 (0.35–0.84)	1.00 (ref)	0.04	0.006
Myocardial infarction	0.80 (0.51–1.26)	0.74 (0.46–1.19)	1.00 (ref)	0.34	0.22
Death from cardiovascular causes	0.69 (0.41–1.16)	1.01 (0.61–1.66)	1.00 (ref)	0.17	0.98
Death from any cause	0.82 (0.64–1.07)	0.97 (0.74–1.26)	1.00 (ref)	0.15	0.82

Table 3. (Continued.)

End Point	Mediterranean Diet with EVOO (N=2543)	Mediterranean Diet with Nuts (N=2454)	Control Diet (N=2450)	P Value†	
				Mediterranean Diet with EVOO vs. Control Diet	Mediterranean Diet with Nuts vs. Control Diet
Hazard ratio for Mediterranean diets combined vs. control (95% CI)					
Primary end point					
Unadjusted	0.70 (0.55–0.89)		1 (ref)		0.003
Multivariable-adjusted 1§	0.71 (0.56–0.90)		1 (ref)		0.004
Multivariable-adjusted 2¶	0.71 (0.56–0.90)		1 (ref)		0.005
Secondary end points					
Stroke	0.61 (0.44–0.86)		1 (ref)		0.005
Myocardial infarction	0.77 (0.52–1.15)		1 (ref)		0.20
Death from cardiovascular causes	0.83 (0.54–1.29)		1 (ref)		0.41
Death from any cause	0.89 (0.71–1.12)		1 (ref)		0.32

\* CI denotes confidence interval, and ref reference.

† All P values were calculated with the use of Cox proportional-hazards models with robust variance estimators and stratification according to recruiting center.

‡ The primary end point was a composite of myocardial infarction, stroke, and death from cardiovascular causes.

§ The primary end point was stratified according to recruiting center and adjusted for sex, age (continuous variable), family history of premature coronary heart disease (yes or no), and smoking status (never smoked, former smoker, or current smoker).

¶ The primary end point was additionally adjusted for body-mass index (continuous variable), waist-to-height ratio (continuous variable), hypertension at baseline (yes or no), dyslipidemia at baseline (yes or no), and diabetes at baseline (yes or no).

|| The secondary end points were stratified according to recruiting center and adjusted for sex, age (continuous variable), family history of premature coronary heart disease (yes or no), smoking status (never smoked, former smoker, or current smoker), body-mass index (continuous variable), waist-to-height ratio (continuous variable), hypertension at baseline (yes or no), dyslipidemia at baseline (yes or no), and diabetes at baseline (yes or no).

## END POINTS


The median follow-up period was 4.8 years. A total of 288 primary-outcome events occurred: 96 in the group assigned to a Mediterranean diet with extra-virgin olive oil (3.8%), 83 in the group assigned to a Mediterranean diet with nuts (3.4%), and 109 in the control group (4.4%). Taking into account the small differences in the accrual of person-years among the three groups, the respective rates of the primary end point were 8.1, 8.0, and 11.2 per 1000 person-years (Table 3). The unadjusted hazard ratios were 0.70 (95% confidence interval [CI], 0.53 to 0.91) for a Mediterranean diet with extra-virgin olive oil and 0.70 (95% CI, 0.53 to 0.94) for a Mediterranean diet with nuts (Fig. 1) as compared with the control diet (P=0.015, by the likelihood ratio test, for the overall effect of the intervention).

The results of multivariate analyses showed a similar protective effect of the two Mediterranean diets versus the control diet with respect to

the primary end point (Table 3). Regarding components of the primary end point, only the comparisons of stroke risk reached statistical significance (Table 3, and Fig. S6 in the Supplementary Appendix). The Kaplan–Meier curves for the primary end point diverged soon after the trial started, but no effect on all-cause mortality was apparent (Fig. 1). The results of several sensitivity analyses were also consistent with the findings of the primary analysis (Table S9 in the Supplementary Appendix).

## SUBGROUP ANALYSES

Reductions in disease risk in the two Mediterranean-diet groups as compared with the control group were similar across the prespecified subgroups (Fig. 2, and Table S10 in the Supplementary Appendix). In addition, to account for the protocol change in October 2006 whereby the intensity of dietary intervention in the control group was increased, we compared hazard ratios




for the Mediterranean-diet groups (both groups merged vs. the control group) before and after this date. Adjusted hazard ratios were 0.77 (95% CI, 0.59 to 1.00) for participants recruited before October 2006 and 0.49 (95% CI, 0.26 to 0.92) for those recruited thereafter (P=0.21 for interaction).

**DISCUSSION**

In this trial, an energy-unrestricted Mediterranean diet supplemented with either extra-virgin olive oil or nuts resulted in an absolute risk reduction of approximately 3 major cardiovascular





**Figure 2. Results of Subgroup Analyses.**

Shown are adjusted hazard ratios for the primary end point within specific subgroups. Squares denote hazard ratios; horizontal lines represent 95% confidence intervals. Hazard ratios indicate the relative risk in both intervention groups merged together (vs. the control group) within each stratum. Hazard ratios were stratified according to recruiting center and were adjusted for sex, age (continuous variable), family history of premature coronary heart disease (CHD) (yes or no), smoking (never smoked, former smoker, or current smoker), body-mass index (BMI) (continuous variable), waist-to-height ratio (continuous variable), hypertension at baseline (yes or no), dyslipidemia at baseline (yes or no), and diabetes at baseline (yes or no). Scores for adherence to the Mediterranean diet range from 0 to 14, with higher scores indicating greater adherence.

events per 1000 person-years, for a relative risk reduction of approximately 30%, among high-risk persons who were initially free of cardiovascular disease. These results support the benefits of the Mediterranean diet for cardiovascular risk

reduction. They are particularly relevant given the challenges of achieving and maintaining weight loss. The secondary prevention Lyon Diet Heart Study also showed a large reduction in rates of coronary heart disease events with a modified

Mediterranean diet enriched with alpha-linolenic acid (a key constituent of walnuts). That result, however, was based on only a few major events.<sup>4,19,20</sup>

There were small between-group differences in some baseline characteristics in our trial, which were not clinically meaningful but were statistically significant, and we therefore adjusted for these variables. In fully adjusted analyses, we found significant results for the combined cardiovascular end point and for stroke, but not for myocardial infarction alone. This could be due to stronger effects on specific risk factors for stroke but also to a lower statistical power to identify effects on myocardial infarction. Our findings are consistent with those of prior observational studies of the cardiovascular protective effects of the Mediterranean diet,<sup>2,5</sup> olive oil,<sup>21-23</sup> and nuts<sup>24,25</sup>; smaller trials assessing effects on traditional cardiovascular risk factors<sup>6-9</sup> and novel risk factors, such as markers of oxidation, inflammation, and endothelial dysfunction<sup>6,8,26-28</sup>; and studies of conditions associated with high cardiovascular risk — namely, the metabolic syndrome<sup>6,16,29</sup> and diabetes.<sup>30-32</sup> Thus, a causal role of the Mediterranean diet in cardiovascular prevention has high biologic plausibility. The results of our trial might explain, in part, the lower cardiovascular mortality in Mediterranean countries than in northern European countries or the United States.<sup>33</sup>

The risk of stroke was reduced significantly in the two Mediterranean-diet groups. This is consistent with epidemiologic studies that showed an inverse association between the Mediterranean diet<sup>2,34</sup> or olive-oil consumption<sup>22</sup> and incident stroke.

Our results compare favorably with those of the Women's Health Initiative Dietary Modification Trial, wherein a low-fat dietary approach resulted in no cardiovascular benefit.<sup>35</sup> Salient components of the Mediterranean diet reportedly associated with better survival include moderate consumption of ethanol (mostly from wine), low consumption of meat and meat products, and high consumption of vegetables, fruits, nuts, legumes, fish, and olive oil.<sup>36,37</sup> Perhaps there is a synergy among the nutrient-rich foods included in the Mediterranean diet that fosters favorable changes in intermediate pathways of cardiometabolic risk, such as blood lipids, insulin sensitivity, resistance to oxidation, inflammation, and vasoreactivity.<sup>38</sup>

Our study has several limitations. First, the protocol for the control group was changed halfway through the trial. The lower intensity of dietary intervention for the control group during the first few years might have caused a bias toward a benefit in the two Mediterranean-diet groups, since the participants in these two groups received a more intensive intervention during that time. However, we found no significant interaction between the period of trial enrollment (before vs. after the protocol change) and the benefit in the Mediterranean-diet groups. Second, we had losses to follow-up, predominantly in the control group, but the participants who dropped out had a worse cardiovascular risk profile at baseline than those who remained in the study, suggesting a bias toward a benefit in the control group. Third, the generalizability of our findings is limited because all the study participants lived in a Mediterranean country and were at high cardiovascular risk; whether the results can be generalized to persons at lower risk or to other settings requires further research.

As with many clinical trials, the observed rates of cardiovascular events were lower than anticipated, with reduced statistical power to separately assess components of the primary end point. However, favorable trends were seen for both stroke and myocardial infarction. We acknowledge that, even though participants in the control group received advice to reduce fat intake, changes in total fat were small and the largest differences at the end of the trial were in the distribution of fat subtypes. The interventions were intended to improve the overall dietary pattern, but the major between-group differences involved the supplemental items. Thus, extra-virgin olive oil and nuts were probably responsible for most of the observed benefits of the Mediterranean diets. Differences were also observed for fish and legumes but not for other food groups. The small between-group differences in the diets during the trial are probably due to the facts that for most trial participants the baseline diet was similar to the trial Mediterranean diet and that the control group was given recommendations for a healthy diet, suggesting a potentially greater benefit of the Mediterranean diet as compared with Western diets.

In conclusion, in this primary prevention trial, we observed that an energy-unrestricted Mediterranean diet, supplemented with extra-virgin

olive oil or nuts, resulted in a substantial reduction in the risk of major cardiovascular events among high-risk persons. The results support the benefits of the Mediterranean diet for the primary prevention of cardiovascular disease.

Supported by the official funding agency for biomedical research of the Spanish government, Instituto de Salud Carlos III (ISCIII), through grants provided to research networks specifically developed for the trial (RTIC G03/140, to Dr. Estruch; RTIC RD 06/0045, to Dr. Martínez-González and through Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición [CIBERObn]), and by grants from Centro Nacional de Investigaciones Cardiovasculares (CNIC 06/2007), Fondo de Investigación Sanitaria—Fondo Europeo de Desarrollo Regional (PI04-2239, PI 05/2584, CP06/00100, PI07/0240, PI07/1138, PI07/0954, PI 07/0473, PI10/01407, PI10/02658, PI11/01647, and PI11/02505), Ministerio de Ciencia e Innovación (AGL-2009-13906-C02 and AGL2010-22319-C03), Fundación Mapfre 2010, Consejería de Salud de la Junta de Andalucía (PI0105/2007), Public Health Division of the Department of Health of the Autonomous Government of Catalonia, Generalitat Valenciana (ACOMP06109, GVACOMP2010-181, GVACOMP2011-151, CS2010-AP-111, and CS2011-AP-042), and Regional Government of Navarra (P27/2011).

Dr. Estruch reports serving on the board of and receiving lecture fees from the Research Foundation on Wine and Nutrition (FIVIN); serving on the boards of the Beer and Health Foundation and the European Foundation for Alcohol Research (ERAB); receiving lecture fees from Cerveceros de España and Sanofi-Aventis; and receiving grant support through his institution from Novartis. Dr. Ros reports serving on the board of and receiving travel support, as well as grant support through his institution, from the California Walnut Commission; serving on the board of the Flora Foundation (Unilever); serving on the board of and receiving lecture fees from Roche; serving on the board of and receiving grant support through his institution from Amgen; receiving consulting fees from Damm and Abbott

Laboratories; receiving consulting fees and lecture fees, as well as grant support through his institution, from Merck; receiving lecture fees from Danone, Pace, AstraZeneca, and Rottapharm; receiving lecture fees and payment for the development of educational presentations, as well as grant support through his institution, from Ferrer; receiving payment for the development of educational presentations from Recordati; and receiving grant support through his institution from Sanofi-Aventis, Takeda, Daiichi Sankyo, Nutrexp, Feiraco, Unilever, and Karo Bio. Dr. Salas-Salvadó reports serving on the board of and receiving grant support through his institution from the International Nut and Dried Fruit Council; receiving consulting fees from Danone; and receiving grant support through his institution from Eroski and Nestlé. Dr. Arós reports receiving payment for the development of educational presentations from Menarini and AstraZeneca. Dr. Lamuela-Raventós reports serving on the board of and receiving lecture fees from FIVIN; receiving lecture fees from Cerveceros de España; and receiving lecture fees and travel support from PepsiCo. Dr. Serra-Majem reports serving on the boards of the Mediterranean Diet Foundation and the Beer and Health Foundation. Dr. Pintó reports serving on the board of and receiving grant support through his institution from the Residual Risk Reduction Initiative (R3i) Foundation; serving on the board of Omegafort; serving on the board of and receiving payment for the development of educational presentations, as well as grant support through his institution, from Ferrer; receiving consulting fees from Abbott Laboratories; receiving lecture fees, as well as grant support through his institution, from Merck and Roche; receiving lecture fees from Danone and Esteve; receiving payment for the development of educational presentations from Menarini; and receiving grant support through his institution from Sanofi-Aventis, Kowa, Unilever, Boehringer Ingelheim, and Karo Bio. No other potential conflict of interest relevant to this article was reported.

Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.

We thank the participants in the trial for their enthusiastic and sustained collaboration and Joan Vila from Institut Municipal d'Investigació Mèdica, Barcelona, for expert assessment in the statistical analyses.

#### APPENDIX

The author's affiliations are as follows: Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición (R.E., E.R., J.S.-S., M.-I.C., D.C., M.F., J.L., R.M.L.-R., J.B., J.V.S., J.A.M.) and the PREDIMED (Prevención con Dieta Mediterránea) Network (RD 06/0045) (R.E., J.S.-S., F.A., E.G.-G., V.R.-G., R.M.L.-R., L.S.-M., X.P., J.B., J.V.S., J.A.M., M.A.M.-G.), Instituto de Salud Carlos III, Madrid; the Department of Internal Medicine (R.E.) and Lipid Clinic, Department of Endocrinology and Nutrition (E.R.), Institut d'Investigacions Biomèdiques August Pi I Sunyer, Hospital Clinic, University of Barcelona, Barcelona; Human Nutrition Department, Hospital Universitari Sant Joan, Institut d'Investigació Sanitària Pere Virgili, Universitat Rovira i Virgili, Reus (J.S.-S.); Cardiovascular and Nutrition Research Group, Institut de Recerca Hospital del Mar, Barcelona (M.-I.C.); the Department of Preventive Medicine, University of Valencia, Valencia (D.C.); the Department of Cardiology, University Hospital of Alava, Vitoria (F.A.); the Department of Preventive Medicine, University of Malaga, Malaga (E.G.-G.); Instituto de la Grasa, Consejo Superior de Investigaciones Científicas, Seville (V.R.-G.); Institute of Health Sciences (IUNICS), University of Balearic Islands, and Hospital Son Espases, Palma de Mallorca (M.F.); the Department of Family Medicine, Primary Care Division of Seville, San Pablo Health Center, Seville (J.L.); the Department of Nutrition and Food Science, School of Pharmacy, Xarxa de Referència en Tecnologia dels Aliments, Instituto de Investigación en Nutrición y Seguridad Alimentaria, University of Barcelona, Barcelona (R.M.L.-R.); the Department of Clinical Sciences, University of Las Palmas de Gran Canaria, Las Palmas (L.S.-M.); Lipids and Vascular Risk Unit, Internal Medicine, Hospital Universitario de Bellvitge, Hospitalet de Llobregat, Barcelona (X.P.); Primary Care Division, Catalan Institute of Health, Institut d'Investigació en Atenció Primària Jordi Gol, Tarragona-Reus (J.B.) and Barcelona (M.A.M.); Primary Care Division, Valencia Institute of Health, Valencia (J.V.S.); and the Departments of Nutrition and Food Sciences, Physiology and Toxicology (J.A.M.) and Preventive Medicine and Public Health (M.A.M.-G.), University of Navarra, Pamplona — all in Spain.

#### REFERENCES

1. Willett WC, Sacks F, Trichopoulos A, et al. Mediterranean diet pyramid: a cultural model for healthy eating. *Am J Clin Nutr* 1995;61:Suppl:1402S-1406S.
2. Sofi F, Abbate R, Gensini GF, Casini A. Accruing evidence on benefits of adherence to the Mediterranean diet on health: an updated systematic review and meta-analysis. *Am J Clin Nutr* 2010;92:1189-96.
3. Serra-Majem L, Roman B, Estruch R. Scientific evidence of interventions using the Mediterranean diet: a systematic review. *Nutr Rev* 2006;64:S27-S47.
4. de Lorgeril M, Salen P, Martin JL,

- Monojad I, Delaye J, Mamelle N. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. *Circulation* 1999;99:779-85.
5. Mente A, de Koning L, Shannon HS, Anand SS. A systematic review of the evidence supporting a causal link between dietary factors and coronary heart disease. *Arch Intern Med* 2009;169:659-69.
  6. Esposito K, Marfella R, Ciotola M, et al. Effect of a Mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial. *JAMA* 2004; 292:1440-6.
  7. Vincent-Baudry S, Defoort C, Gerber M, et al. The Medi-RIVAGE study: reduction of cardiovascular disease risk factors after a 3-mo intervention with a Mediterranean-type diet or a low-fat diet. *Am J Clin Nutr* 2005;82:964-71.
  8. Estruch R, Martínez-González MA, Corella D, et al. Effects of a Mediterranean-style diet on cardiovascular risk factors: a randomized trial. *Ann Intern Med* 2006;145:1-11.
  9. Shai I, Schwarzfuchs D, Henkin Y, et al. Weight loss with a low-carbohydrate, Mediterranean, or low-fat diet. *N Engl J Med* 2008;359:229-41. [Erratum, *N Engl J Med* 2009;361:2681.]
  10. Martínez-González MA, Corella D, Salas-Salvadó J, et al. Cohort profile: design and methods of the PREDIMED study. *Int J Epidemiol* 2012;41:377-85.
  11. The PREDIMED Study (<http://www.predimed.org>).
  12. The PREDIMED network (<http://www.predimed.es>).
  13. Zazpe I, Sanchez-Tainta A, Estruch R, et al. A large randomized individual and group intervention conducted by registered dietitians increased the adherence to Mediterranean-type diets: the PREDIMED study. *J Am Diet Assoc* 2008;108:1134-44.
  14. Schröder H, Fitó M, Estruch R, et al. A short screener is valid for assessing Mediterranean diet adherence among older Spanish men and women. *J Nutr* 2011; 141:1140-5.
  15. Fernández-Ballart JD, Piñol JL, Zazpe I, et al. Relative validity of a semi-quantitative food-frequency questionnaire in an elderly Mediterranean population of Spain. *Br J Nutr* 2010;103:1808-16.
  16. Salas-Salvadó J, Fernández-Ballart J, Ros E, et al. Effect of a Mediterranean diet supplemented with nuts on metabolic syndrome status: one-year results of the PREDIMED randomized trial. *Arch Intern Med* 2008;168:2449-58.
  17. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). *JAMA* 2002;288:2998-3007.
  18. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. *Biometrics* 1979;35:549-56.
  19. Kris-Etherton P, Eckel RH, Howard BV, St Jeor S, Bazzarre TL. Lyon Diet Heart Study: benefits of a Mediterranean-style, National Cholesterol Education Program/American Heart Association step I dietary pattern on cardiovascular disease. *Circulation* 2001;103:1823-5.
  20. de Lorgeril M, Renaud S, Mamelle N, et al. Mediterranean alpha-linolenic acid-rich diet in secondary prevention of coronary heart disease. *Lancet* 1994;343:1454-9. [Erratum, *Lancet* 1995;345:738.]
  21. Bendinelli B, Masala G, Saieva C, et al. Fruit, vegetables, and olive oil and risk of coronary heart disease in Italian women: the EPICOR Study. *Am J Clin Nutr* 2011; 93:275-83.
  22. Samieri C, Féart C, Proust-Lima C, et al. Olive oil consumption, plasma oleic acid, and stroke incidence: the Three-City Study. *Neurology* 2011;77:418-25.
  23. Buckland G, Travier N, Barricarte A, et al. Olive oil intake and CHD in the European Prospective Investigation into Cancer and Nutrition Spanish cohort. *Br J Nutr* 2012;108:2075-82.
  24. Kris-Etherton PM, Hu FB, Ros E, Sabaté J. The role of tree nuts and peanuts in the prevention of coronary heart disease: multiple potential mechanisms. *J Nutr* 2008;138:1746S-1751S.
  25. Ros E, Tapsell LC, Sabaté J. Nuts and berries for heart health. *Curr Atheroscler Rep* 2010;12:397-406.
  26. Fitó M, Guxens M, Corella D, et al. Effect of a traditional Mediterranean diet on lipoprotein oxidation: a randomized controlled trial. *Arch Intern Med* 2007; 167:1195-203.
  27. Mena MP, Sacanella E, Vázquez-Agell M, et al. Inhibition of circulating immune cell activation: a molecular antiinflammatory effect of the Mediterranean diet. *Am J Clin Nutr* 2009;89:248-56.
  28. Fuentes F, López-Miranda J, Sánchez E, et al. Mediterranean and low-fat diets improve endothelial function in hypercholesterolemic men. *Ann Intern Med* 2001;134:1115-9.
  29. Kastorini CM, Milionis HJ, Esposito K, Giugliano D, Goudevenos JA, Panagiotakos DB. The effect of Mediterranean diet on metabolic syndrome and its components: a meta-analysis of 50 studies and 534,906 individuals. *J Am Coll Cardiol* 2011;57:1299-313.
  30. Esposito K, Maiorino MI, Ceriello A, Giugliano D. Prevention and control of type 2 diabetes by Mediterranean diet: a systematic review. *Diabetes Res Clin Pract* 2010;89:97-102.
  31. Salas-Salvadó J, Bulló M, Babio N, et al. Reduction in the incidence of type 2 diabetes with the Mediterranean diet: results of the PREDIMED-Reus nutrition intervention randomized trial. *Diabetes Care* 2011;34:14-9.
  32. Martínez-González MA, de la Fuente-Arillaga C, Nuñez-Córdoba JM, et al. Adherence to Mediterranean diet and risk of developing diabetes: prospective cohort study. *BMJ* 2008;336:1348-51.
  33. Müller-Nordhorn J, Binting S, Roll S, Willich SN. An update on regional variation in cardiovascular mortality within Europe. *Eur Heart J* 2008;29:1316-26.
  34. Kastorini CM, Milionis HJ, Ioannidi A, et al. Adherence to the Mediterranean diet in relation to acute coronary syndrome or stroke nonfatal events: a comparative analysis of a case/control study. *Am Heart J* 2011;162:717-24.
  35. Howard BV, Van Horn L, Hsia J, et al. Low-fat dietary pattern and risk of cardiovascular disease: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. *JAMA* 2006;295:655-66.
  36. Trichopoulou A, Bamia C, Trichopoulos D. Anatomy of health effects of Mediterranean diet: Greek EPIC prospective cohort study. *BMJ* 2009;338:b2337.
  37. Buckland G, Mayén AL, Agudo A, et al. Olive oil intake and mortality within the Spanish population (EPIC-Spain). *Am J Clin Nutr* 2012;96:142-9.
  38. Jacobs DR Jr, Gross MD, Tapsell LC. Food synergy: an operational concept for understanding nutrition. *Am J Clin Nutr* 2009;89:1543S-1548S.

Copyright © 2013 Massachusetts Medical Society.

RECEIVE IMMEDIATE NOTIFICATION WHEN AN ARTICLE  
IS PUBLISHED ONLINE FIRST

To be notified by e-mail when *Journal* articles  
are published Online First, sign up at [NEJM.org](http://NEJM.org).